Opaleye Management Inc. Revance Therapeutics, Inc. Transaction History
Opaleye Management Inc.
- $411 Million
- Q1 2024
A detailed history of Opaleye Management Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 785,000 shares of RVNC stock, worth $2.02 Million. This represents 0.94% of its overall portfolio holdings.
Number of Shares
785,000
Previous 785,000
-0.0%
Holding current value
$2.02 Million
Previous $3.86 Million
-0.0%
% of portfolio
0.94%
Previous 0.95%
Shares
1 transactions
Others Institutions Holding RVNC
# of Institutions
214Shares Held
83.4MCall Options Held
656KPut Options Held
424K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.31MShares$18.8 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.28MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.4MShares$13.9 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.25MShares$13.5 Million3.02% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...